+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

The 2019 Worldwide Market for Targeted Cancer Therapeutics

  • ID: 4767214
  • Report
  • Region: Global
  • 177 Pages
  • Kalorama Information
1 of 4

FEATURED COMPANIES

  • AbbVie, Inc.
  • Aurobindo Pharma Ltd.
  • Celsion Corporation
  • Gilead Sciences, Inc.
  • Novartis AG
  • Sanofi
  • MORE

The publisher has watched the cancer treatment market evolve over the past two decades and evaluated the impact new technologies are making on the market. The 2019 Worldwide Market for Targeted Cancer Therapeutics focuses on the expanding area of targeted therapies and includes current products available and discusses some of the most exciting developments in progress.

This report covers targeted cancer therapies that do at least one of the following:

  • Block or turn off chemical signals that tell the cancer cell to grow and divide
  • Change proteins within the cancer cells so the cells die
  • Stop making new blood vessels to feed the cancer cells
  • Trigger the immune system to kill the cancer cells
  • Carry toxins to the cancer cells to kill them, but not normal cells

This report on the targeted cancer therapeutics market specifically focuses on five leading segments of targeted therapies - monoclonal antibodies, tyrosine kinase inhibitors, angiogenesis inhibitors, CDK inhibitors, and proteasome inhibitors - providing information on a global level, including:

  • Global Targeted Cancer Therapeutic Market Size and Forecast, 2010-2025 ($millions) (monoclonal antibodies, tyrosine kinase inhibitors, angiogenesis inhibitors, proteasome inhibitors, CDK inhibitors, others)
  • Cancer Monoclonal Antibody Market, 2018-2025 ($ millions)
  • Top 10 Cancer Indicated Monoclonal Antibodies, 2017 and 2018 Sales (millions $)
  • Monoclonal Antibodies in Cancer Therapy (Trade Name, Biological Name, Target, Indication[s])
  • Tyrosine Kinase Inhibitor Market, 2018-2025 ($ millions)
  • Top 10 Cancer Indicated Tyrosine Kinase Inhibitors, 2017 and 2018 Sales (millions $)
  • Tyrosine Kinase Inhibitors in Cancer Therapy (Trade Name, Biological Name, Target, Indication[s])
  • Angiogenesis Inhibitor Market, 2018-2025 ($ millions)
  • Angiogenesis Inhibitors in Cancer Therapy (Trade Name, Biological Name, Indication[s])
  • CDK Inhibitor Market, 2018-2025: ($ millions)
  • CDK Inhibitors in Cancer Therapy (Trade Name, Biological Name, Target, Indication[s])
  • Proteasome Inhibitor Market, 2018-2025: ($ millions)
  • Proteasome Inhibitors in Cancer Therapy (Trade Name, Biological Name, Target, Indication[s])
  • Other Targeted Therapies Market, 2018-2025: ($ millions)
  • Other Targeted Cancer Therapies (Classification, Trade Name, Biological Name, Target, Indication[s])

The report also provides specific information by type and by target on a global level for the monoclonal antibodies (mAbs) and tyrosine kinase inhibitors (TKI) segments, including:

Cancer Monoclonal Antibody Market by Type

  • Development of the mAb Cancer Treatment Market, 2010-2025 (Breast Cancer, Colorectal Cancer, Lymphoma, Leukemia, Myeloma, Melanoma, Lung, Renal, Others)
  • Monoclonal Antibody Market by Cancer Type, 2018 and 2025 ($ millions) (Breast, Lymphoma, Lung, Colorectal, Melanoma, Multiple Myeloma, Kidney, Leukemia, Ovarian, Urothelial, Head/Neck, GIST, Brain, Sarcoma, Liver, Other Solid Tumors, Other undisclosed/Unknown)
  • Monoclonal Antibody Market, Distribution by Cancer Type, 2018 (%) (Breast, Lymphoma, Lung, Colorectal, Melanoma, Multiple Myeloma, Kidney, Leukemia, Ovarian, Urothelial, Head/Neck, GIST, Brain, Sarcoma, Liver, Other Solid Tumors, Other undisclosed/Unknown)
  • Monoclonal Antibody Market Distribution by Indication, 2025 (%) (Breast, Lymphoma, Lung, Colorectal, Melanoma, Multiple Myeloma, Kidney, Leukemia, Ovarian, Urothelial, Head/Neck, GIST, Brain, Sarcoma, Liver, Other Solid Tumors, Other undisclosed/Unknown)

Cancer Tyrosine Kinase Inhibitor Market by Type

  • Development of the TKI Cancer Treatment Market, 2010-2025 (Leukemia, Lung, Lymphoma, Kidney, Melanoma, GIST, Liver, Pancreatic, Breast, Thyroid, Colorectal, Other)
  • TKI Market by Cancer Indication, 2018 and 2025 ($ millions) (Leukemia, Lung, Lymphoma, Kidney, Melanoma, GIST, Liver, Pancreatic, Breast, Thyroid, Colorectal, Other)
  • TKI Market Distribution by Cancer Indication, 2018 (%) (Leukemia, Lung, Lymphoma, Kidney, Melanoma, GIST, Liver, Pancreatic, Breast, Thyroid, Colorectal, Other)
  • TKI Market Distribution by Cancer Indication, 2025 (%) (Leukemia, Lung, Lymphoma, Kidney, Melanoma, GIST, Liver, Pancreatic, Breast, Thyroid, Colorectal, Other)

Cancer Monoclonal Antibody Market by Target

  • Cancer Monoclonal Antibody Market by Target, 2018 and Forecast 2025 ($ millions) (PD-1, HER2, VEGF, CD20, EGFR, CD38, RANKL, CTLA-4, PD-L1, CD30, PDGF)
  • Cancer Monoclonal Antibody Market Distribution by Target, 2018 (%) (PD-1, HER2, VEGF, CD20, EGFR, CD38, RANKL, CTLA-4, PD-L1, CD30, PDGF)
  • Cancer Monoclonal Antibody Market Distribution by Target, 2025 (%) (PD-1, HER2, VEGF, CD20, EGFR, CD38, RANKL, CTLA-4, PD-L1, CD30, PDGF)

Cancer Tyrosine Kinase Inhibitor Market by Target

  • Cancer TKI Market by Target, 2018 and Forecast 2025 ($ millions) (Single Target: ALK, ABL, BTK, EGFR, VEGF, HER2, BRAF, Others; Multi-target)
  • TKI Market Distribution by Target, 2018 (%) (ALK, ABL, BTK, EGFR, VEGF, HER2, BRAF, Others; Multi-target)
  • TKI Market Distribution by Target, 2025 (%) (ALK, ABL, BTK, EGFR, VEGF, HER2, BRAF, Others; Multi-target)

The United States cancer pharmaceutical industry is the largest in terms of revenues generated. Western European markets are major drivers for innovative cancer treatment markets with growing sales in emerging Eastern European markets. Asia Pacific sales are driven by established economies such as Japan and Australia and emerging markets such as China. Cancer treatment markets have been slower to develop in Latin American markets, with targeted therapies often secondary to traditional chemotherapy or hormone therapy. The 2019 Worldwide Market for Targeted Cancer Therapeutics provides regional market overviews, encompassing United States and Canada; Europe, Middle East and Africa (EMEA); Asia Pacific; and Latin America:

Targeted Cancer Therapeutics Market Summary by Geographical Region, 2018-2025 ($ millions) (United States and Canada; Europe, Middle East, Africa (EMEA); Asia Pacific; Latin America; Global Market)

United States and Canada

  • Targeted Cancer Therapeutics Market Summary for U.S. and Canada, 2018-2025 ($ millions) (Monoclonal antibodies, Tyrosine kinase inhibitors, Angiogenesis Inhibitors, Proteasome inhibitors, CDK inhibitors, Other targeted therapies, Total)
  • Targeted Cancer Therapeutics for U.S. and Canada, Distribution by Therapy Type (monoclonal antibodies, tyrosine kinase inhibitors, angiogenesis inhibitors, proteasome inhibitors, CDK inhibitors, other targeted therapies), 2018 %

EMEA

  • Targeted Cancer Therapeutics Market Summary for EMEA, 2018-2025 ($ millions) (Monoclonal antibodies, Tyrosine kinase inhibitors, Angiogenesis Inhibitors, Proteasome inhibitors, CDK inhibitors, Other targeted therapies, Total)
  • Targeted Cancer Therapeutics for EMEA, Distribution by Therapy Type (monoclonal antibodies, tyrosine kinase inhibitors, angiogenesis inhibitors, proteasome inhibitors, CDK inhibitors, other targeted therapies), 2018 %

Asia Pacific

  • Targeted Cancer Therapeutics Market Summary for the Asia Pacific, 2018-2025 ($ millions) (Monoclonal antibodies, Tyrosine kinase inhibitors, Angiogenesis Inhibitors, Proteasome inhibitors, CDK inhibitors, Other targeted therapies, TotaTargeted Cancer
  • Therapeutics for the Asia Pacific, Distribution by Therapy Type (monoclonal antibodies, tyrosine kinase inhibitors, angiogenesis inhibitors, proteasome inhibitors, CDK inhibitors, other targeted therapies), 2018 %

Latin America

  • Targeted Cancer Therapeutics Market Summary for Latin America, 2018-2025 ($ millions) (Monoclonal antibodies, Tyrosine kinase inhibitors, Angiogenesis Inhibitors, Proteasome inhibitors, CDK inhibitors, Other targeted therapies, Total)
  • Targeted Cancer Therapeutics for Latin America, Distribution by Therapy Type (monoclonal antibodies, tyrosine kinase inhibitors, angiogenesis inhibitors, proteasome inhibitors, CDK inhibitors, other targeted therapies), 2018 %

The report includes competitive summaries of the leading market providers. In addition, the report provides competitor market share in major market segments, including:

  • Cancer Monoclonal Antibody Competitor Market Share - Top Seven, 2018 ($ millions)
  • Cancer TKI Competitor Market Share, 2018 ($ millions)
  • Cancer CDK Inhibitors Competitor Market Share, 2018 ($ millions)
  • Cancer Proteasome Inhibitor Competitor Market Share, 2018 ($ millions)

The 2019 Worldwide Market for Targeted Cancer Therapeutics concludes with profiles of the leading competitors in the targeted cancer therapeutic market, including:

  • AbbVie, Inc.
  • Adaptimmune Therapeutics plc.
  • Advantagene, Inc.
  • Agenus, Inc.
  • Amgen
  • Anchiano Therapeutics
  • Apceth Biopharma GmbH & Co. KG
  • Apollomics, Inc.
  • Aptevo Therapeutics
  • AstraZeneca PLC
  • Aurobindo Pharma Ltd.
  • Bayer AG
  • Bellicum Pharmaceuticals, Inc.
  • Biocon Ltd
  • BioInvent International AB
  • bluebird bio, Inc.
  • Boehringer Ingelheim
  • Bristol-Myers Squibb Company
  • Celgene Corporation
  • Celldex Therapeutics
  • Celltrion, Inc.
  • Celsion Corporation
  • Clovis Oncology, Inc.
  • Cold Genesys, Inc.
  • Dendreon Pharmaceuticals LLC
  • Eisai Co., Ltd.
  • Eli Lilly & Company
  • EMD Serono, Inc. (Merck KgaA)
  • Exelixis, Inc.
  • Gamida Cell Ltd.
  • Genprex, Inc.
  • Gilead Sciences, Inc.
  • Immunomedics, Inc.
  • Incyte Corporation
  • Innate Pharma S.A.
  • Inovio Pharmaceuticals, Inc.
  • Johnson & Johnson
  • MacroGenics, Inc.
  • Merck & Co., Inc.
  • Merrimack Pharmaceuticals, Inc.
  • Nascent Biotech
  • Northwest Biotherapeutics, Inc.
  • Novartis AG
  • Oncolytics Biotech, Inc.
  • OncoMed Pharmaceuticals, Inc.
  • OncoSec Medical, Inc.
  • Oncternal Therapeutics
  • Otsuka Holdings Co., Ltd.
  • Pfizer, Inc.
  • Puma Biotechnology, Inc.
  • Regeneron Pharmaceuticals
  • Roche (F. Hoffman-La Roche, Ltd.)
  • Sanofi
  • Seattle Genetics, Inc.
  • Sesen Bio
  • Sorrento Therapeutics
  • Takeda Oncology - Millennium Pharmaceuticals
  • TESARO, Inc.
  • TG Therapeutics, Inc.
  • Tocagen, Inc.
  • Vascular Biogenics Ltd.
  • ZIOPHARM Oncology, Inc.
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • AbbVie, Inc.
  • Aurobindo Pharma Ltd.
  • Celsion Corporation
  • Gilead Sciences, Inc.
  • Novartis AG
  • Sanofi
  • MORE

Chapter 1: Executive Summary

  • Overview
  • Scope and Methodology
  • Market Overview and Analysis
  • Figure 1-1: Global Targeted Cancer Therapeutic Market Size and Forecast, 2010-2025 ($millions) (monoclonal antibodies, tyrosine kinase inhibitors, angiogenesis inhibitors, proteasome inhibitors, CDK inhibitors, others)

Chapter 2: Introduction

  • Global Cancer Burden
  • Figure 2-1: Global Cancer Incidence Trends, 2010-2040
  • Figure 2-2: Incidence of Cancer by Type, 2018 (Lung, Breast, Colorectal, Prostate, Stomach, Liver, Oesophagus, Cervix uteri, Thyroid, Bladder)
  • Figure 2-3: Distribution of Cancer Incidence by Type, 2018 (Lung, Breast, Colorectal, Prostate, Stomach, Liver, Oesophagus, Cervix uteri, Thyroid, Bladder, Others)
  • Introduction to Cancer
  • Biochemistry of Cancer Cells
  • Causes of Cancer Growth May Shed Light on Treatment
  • Environmental Factors, DNA, RNA
  • Table 2-1: Virus Association with Human Cancer
  • Cellular Oncogenes
  • Tumor Suppressor Genes
  • Cancer Treatment Approaches
  • Table 2-2: Characteristics of Cancer Treatment Approaches (chemotherapy, hormone therapy, targeted therapy)
  • What Is Targeted Cancer Therapy?
  • Trends in Research and Development of Targeted Cancer Therapeutics
  • Cancer Treatment Market Outlook: Targeted vs. Broad Treatments
  • Figure 2-4: Targeted vs. Broad Treatments for Cancer, 2010-2025
  • Monoclonal Antibodies: The Leading Area of Cancer Targeted Therapy

Chapter 3: Targeted Cancer Therapies: Monoclonal Antibodies

  • Monoclonal Antibody Overview
  • Market Outlook
  • Figure 3-1: Cancer Monoclonal Antibody Market, 2018-2025 ($ millions)
  • Principal Products
  • Table 3-1: Top 10 Cancer Indicated Monoclonal Antibodies, 2017 and 2018 Sales (millions $)
  • Figure 3-2: Top 10 Cancer Indicated Monoclonal Antibodies, 2017 and 2018 Sales (millions $)
  • Avastin (bevacizumab)
  • Darzalex (daratumumab)
  • Erbitux (cetuximab)
  • Herceptin (trastuzumab)
  • Kadcyla (ado-trastuzumab emtansine)
  • Keytruda (pembrolizumab)
  • Opdivo (nivolumab)
  • Perjeta (pertuzumab)
  • Rituxan (rituximab)
  • Yervoy (ipilimumab)
  • Xgeva (denosumab)
  • Table 3-2: Monoclonal Antibodies in Cancer Therapy
  • Market Breakdown of Monoclonal Antibodies
  • Cancer Monoclonal Antibody Market by Target
  • Table 3-3: Cancer Monoclonal Antibody Market by Target, 2018 and Forecast 2025 ($ millions) (PD-1, HER2, VEGF, CD20, EGFR, CD38, RANKL, CTLA-4, PD-L1, CD30, PDGF)
  • Figure 3-3: Cancer Monoclonal Antibody Market by Target, 2018 and 2025 ($ millions) (PD-1, HER2, VEGF, CD20, EGFR, CD38, RANKL, CTLA-4, PD-L1, CD30, PDGF)
  • Figure 3-4: Cancer Monoclonal Antibody Market Distribution by Target, 2018 (%) (PD-1, HER2, VEGF, CD20, EGFR, CD38, RANKL, CTLA-4, PD-L1, CD30, PDGF)
  • Figure 3-5: Cancer Monoclonal Antibody Market Distribution by Target, 2025 (%) (PD-1, HER2, VEGF, CD20, EGFR, CD38, RANKL, CTLA-4, PD-L1, CD30, PDGF)
  • Cancer Monoclonal Antibody Market by Type
  • Figure 3-6: Development of the mAb Cancer Treatment Market, 2010-2025 (Breast Cancer, Colorectal Cancer, Lymphoma, Leukemia, Myeloma, Melanoma, Lung, Renal, Others)
  • Table 3-4: Cancer Treatment mAb Market by Type, 2018-2025 ($ millions) (Breast Cancer, Colorectal Cancer, Lymphoma, Leukemia, Myeloma, Melanoma, Lung Cancer, Renal Cell Carcinoma)
  • Figure 3-7: Monoclonal Antibody Market by Cancer Type, 2018 and 2025 ($ millions) (Breast, Lymphoma, Lung, Colorectal, Melanoma, Multiple Myeloma, Kidney, Leukemia, Ovarian, Urothelial, Head/Neck, GIST, Brain, Sarcoma, Liver, Other Solid Tumors, Other undisclosed/Unknown)
  • Figure 3-8: Monoclonal Antibody Market, Distribution by Cancer Type, 2018 (%) (Breast, Lymphoma, Lung, Colorectal, Melanoma, Multiple Myeloma, Kidney, Leukemia, Ovarian, Urothelial, Head/Neck, GIST, Brain, Sarcoma, Liver, Other Solid Tumors, Other undisclosed/Unknown)
  • Figure 3-9: Monoclonal Antibody Market Distribution by Indication, 2025 (%) (Breast, Lymphoma, Lung, Colorectal, Melanoma, Multiple Myeloma, Kidney, Leukemia, Ovarian, Urothelial, Head/Neck, GIST, Brain, Sarcoma, Liver, Other Solid Tumors, Other undisclosed/Unknown)
  • Regional Market Summary
  • Figure: 3-10: Cancer Monoclonal Antibody Market Summary by Geographic Region, 2018 and 2025 ($ millions) (United States, EMEA, Asia Pacific, Latin America)
  • Competitor Summary
  • Genentech/Roche
  • Bristol-Myers Squibb
  • Merck & Co.
  • Amgen
  • Janssen Biotech/J&J
  • Eli Lilly & Co.
  • EMD Serono
  • Table 3-5: Cancer Monoclonal Antibody Competitor Market Share - Top Seven, 2018 ($ millions)

Chapter 4: Targeted Cancer Therapies: Tyrosine Kinase Inhibitors

  • Tyrosine Kinase Inhibitor Overview
  • Market Outlook
  • Figure 4-1: Tyrosine Kinase Inhibitor Market, 2018-2025 ($ millions)
  • Principal Products
  • Table 4-1: Top 10 Cancer Indicated Tyrosine Kinase Inhibitors, 2017 and 2018 Sales (millions $)
  • Figure 4-2: Top 10 Cancer Indicated Tyrosine Kinase Inhibitors, 2017 and 2018 Sales (millions $)
  • Imbruvica (ibrutinib)
  • Sprycel (dasatinib)
  • Tasigna (nilotinib)
  • Tagrisso (osimertinib)
  • Gleevec (imatinib)
  • Mekinist+Tafinlar (trametinib + dabrafenib)
  • Sutent (sunitinib)
  • Jakafi/Jakavi (ruxolitinib)
  • Nexavar (sorafenib)
  • Votrient (pazopanib)
  • Table 4-2: Tyrosine Kinase Inhibitors in Cancer Therapy
  • Market Breakdown of Tyrosine Kinase Inhibitors
  • Cancer Tyrosine Kinase Inhibitor Market by Target
  • Table 4-3: Cancer TKI Market by Target, 2018 and Forecast 2025 ($ millions) (Single Target: ALK, ABL, BTK, EGFR, VEGF, HER2, BRAF, Others; Multi-target)
  • Figure 4-3: Cancer TKI Market by Target, 2018 and 2025 ($ millions) (ALK, ABL, BTK, EGFR, VEGF, HER2, BRAF, Others; Multi-target)
  • Figure 4-4: TKI Market Distribution by Target, 2018 (%) (ALK, ABL, BTK, EGFR, VEGF, HER2, BRAF, Others; Multi-target)
  • Figure 4-5: TKI Market Distribution by Target, 2025 (%) (ALK, ABL, BTK, EGFR, VEGF, HER2, BRAF, Others; Multi-target)
  • Cancer Tyrosine Kinase Inhibitor Market by Type
  • Figure 4-6: Development of the TKI Cancer Treatment Market, 2010-2025 (Leukemia, Lung, Lymphoma, Kidney, Melanoma, GIST, Liver, Pancreatic, Breast, Thyroid, Colorectal, Other)
  • Table 4-4: Cancer Treatment TKI Market by Type, 2018-2025 ($ millions) (Leukemia, Lung, Lymphoma, Kidney, Melanoma, GIST, Liver, Pancreatic, Breast, Thyroid, Colorectal)
  • Figure 4-7: TKI Market by Cancer Indication, 2018 and 2025 ($ millions) (Leukemia, Lung, Lymphoma, Kidney, Melanoma, GIST, Liver, Pancreatic, Breast, Thyroid, Colorectal, Other)
  • Figure 4-8: TKI Market Distribution by Cancer Indication, 2018 (%) (Leukemia, Lung, Lymphoma, Kidney, Melanoma, GIST, Liver, Pancreatic, Breast, Thyroid, Colorectal, Other)
  • Figure 4-9: TKI Market Distribution by Cancer Indication, 2025 (%) (Leukemia, Lung, Lymphoma, Kidney, Melanoma, GIST, Liver, Pancreatic, Breast, Thyroid, Colorectal, Other)
  • Regional Market Summary
  • Figure: 4-10: Cancer Tyrosine Kinase Inhibitor Market Summary by Geographic Region, 2018 and 2025 ($ millions) (United States, EMEA, Asia Pacific, Latin America)
  • Competitor Summary
  • Novartis
  • AbbVie
  • Johnson & Johnson
  • AstraZeneca
  • Pfizer
  • Bristol-Myers Squibb
  • Roche/Genentech
  • Table 4-5: Cancer TKI Competitor Market Share, 2018 ($ millions)

Chapter 5: Targeted Cancer Therapies: Angiogenesis Inhibitors

  • Angiogenesis Inhibitor Overview
  • Market Outlook
  • Figure 5-1: Angiogenesis Inhibitor Market, 2018-2025 ($ millions)
  • Principal Products
  • Pomalyst/Imnovid (pomalidomide)
  • Revlimid (lenalidomide)
  • Thalomid (thalidomide)
  • Zaltrap (ziv-aflibercept)
  • Table 5-1: Angiogenesis Inhibitors in Cancer Therapy
  • Regional Market Summary
  • Figure: 5-2: Cancer Angiogenesis Inhibitor Market Summary by Geographic Region, Estimated 2018 and 2025 ($ millions) (United States, EMEA, Asia Pacific, Latin America)
  • Competitor Summary

Chapter 6: Targeted Cancer Therapies: CDK Inhibitors

  • CDK Inhibitor Overview
  • Market Outlook
  • Figure 6-1: CDK Inhibitor Market, 2018-2025: ($ millions)
  • Principal Products
  • Ibrance (palbociclib)
  • Kisqali (ribociclib)
  • Table 6-1: CDK Inhibitors in Cancer Therapy
  • Regional Market Summary
  • Figure: 6-2: Cancer CDK Inhibitor Market Summary by Geographic Region, Estimated 2018 and 2025 ($ millions) (United States, EMEA, Asia Pacific, Latin America)
  • Competitor Summary
  • Pfizer
  • Novartis
  • Table 6-2: Cancer CDK Inhibitors Competitor Market Share, 2018 ($ millions)

Chapter 7: Targeted Cancer Therapies: Proteasome Inhibitors

  • Proteasome Inhibitor Overview
  • Market Outlook
  • Figure 7-1: Proteasome Inhibitor Market, 2018-2025: ($ millions)
  • Principal Products
  • Kyprolis (carfilzomib)
  • Ninlaro (ixazomib)
  • Velcade (bortezomib)
  • Table 7-1: Proteasome Inhibitors in Cancer Therapy
  • Regional Market Summary
  • Figure: 7-2: Cancer Proteasome Inhibitor Market Summary by Geographic Region, Estimated 2018 and 2025 ($ millions) (United States, EMEA, Asia Pacific, Latin America)
  • Competitor Summary
  • Takeda
  • Johnson & Johnson
  • Amgen
  • Table 7-2: Cancer Proteasome Inhibitor Competitor Market Share, 2018 ($ millions)

Chapter 8: Targeted Cancer Therapies: Other Targeted Therapies

  • Other Targeted Therapies Overview
  • Market Outlook
  • Figure 8-1: Other Targeted Therapies Market, 2018-2025: ($ millions)
  • Principal Products
  • mTOR Inhibitor ¾ Afinitor (everolimus)
  • mTOR Inhibitor ¾ Torisel (temsirolimus)
  • PI3K Inhibitor ¾ Zydelig
  • PARP Inhibitor ¾ Lynparza
  • PARP Inhibitor ¾ Zejula
  • Apoptosis Inducer ¾ Venclexta
  • Table 8-1: Other Targeted Cancer Therapies
  • Regional Market Summary
  • Figure: 8-2: Other Targeted Therapies Market Summary by Geographic Region, Estimated 2018 and 2025 ($ millions) (United States, EMEA, Asia Pacific, Latin America)

Chapter 9: Market Summary

  • Market Influences
  • Global Demographics
  • Table 9-1: Global Population, 1980 through 2050 (population in millions)
  • Figure 9-1: Global Population Trends, Total Population vs. Age 65+ Population, 2000-2050
  • Cancer: A Growing Economic Burden
  • Cost Containment
  • Table 9-2: The Cost of Monoclonal Antibodies
  • Reimbursement Landscape: A Deciding Factor for Success
  • The Biosimilar Movement
  • Regional Market Overview
  • Table 9-3: Targeted Cancer Therapeutics Market Summary by Geographical Region, 2018-2025 ($ millions) (United States and Canada; Europe, Middle East, Africa (EMEA); Asia Pacific; Latin America; Global Market)
  • United States and Canada
  • Table 9-4: Targeted Cancer Therapeutics Market Summary for U.S. and Canada, 2018-2025 ($ millions) (Monoclonal antibodies, Tyrosine kinase inhibitors, Angiogenesis Inhibitors, Proteasome inhibitors, CDK inhibitors, Other targeted therapies, Total)
  • Figure 9-2: Targeted Cancer Therapeutics for U.S. and Canada, Distribution by Therapy Type (monoclonal antibodies, tyrosine kinase inhibitors, angiogenesis inhibitors, proteasome inhibitors, CDK inhibitors, other targeted therapies), 2018 %
  • EMEA
  • Table 9-5: Targeted Cancer Therapeutics Market Summary for EMEA, 2018-2025 ($ millions) (Monoclonal antibodies, Tyrosine kinase inhibitors, Angiogenesis Inhibitors, Proteasome inhibitors, CDK inhibitors, Other targeted therapies, Total)
  • Figure 9-3: Targeted Cancer Therapeutics for EMEA, Distribution by Therapy Type (monoclonal antibodies, tyrosine kinase inhibitors, angiogenesis inhibitors, proteasome inhibitors, CDK inhibitors, other targeted therapies), 2018 %
  • Asia Pacific
  • Table 9-6: Targeted Cancer Therapeutics Market Summary for Asia Pacific, 2018-2025 ($ millions) (Monoclonal antibodies, Tyrosine kinase inhibitors, Angiogenesis Inhibitors, Proteasome inhibitors, CDK inhibitors, Other targeted therapies, Total)
  • Figure 9-4: Targeted Cancer Therapeutics for Asia Pacific, Distribution by Therapy Type (monoclonal antibodies, tyrosine kinase inhibitors, angiogenesis inhibitors, proteasome inhibitors, CDK inhibitors, other targeted therapies), 2018 %
  • Latin America
  • Table 9-7: Targeted Cancer Therapeutics Market Summary for Latin America, 2018-2025 ($ millions) (Monoclonal antibodies, Tyrosine kinase inhibitors, Angiogenesis Inhibitors, Proteasome inhibitors, CDK inhibitors, Other targeted therapies, Total)
  • Figure 9-5: Targeted Cancer Therapeutics for Latin America, Distribution by Therapy Type (monoclonal antibodies, tyrosine kinase inhibitors, angiogenesis inhibitors, proteasome inhibitors, CDK inhibitors, other targeted therapies), 2018 %

Chapter 10: Market Participants

  • Top 15 Overview
  • Table 10-1: Global Market Participants for Targeted Cancer Therapeutics, Top 15 Companies, 2018 ($ in millions)
  • Figure 10-1: Global Market Share for Targeted Cancer Therapeutics, 2018 %
  • Figure 10-2: Growth in Targeted Cancer Therapeutics by Company 2010 vs. 2018 ($ in millions)
  • Figure 10-3: Growth Trend by Company, 2010-2018 CAGR: Targeted Cancer Therapeutics
  • AbbVie, Inc.
  • Table 10-2: AbbVie Corporate Summary
  • Adaptimmune Therapeutics plc.
  • Table 10-3: Adaptimmune Corporate Summary
  • Advantagene, Inc.
  • Table 10-4: Advantagene Corporate Summary
  • Agenus, Inc.
  • Table 10-5: Agenus Corporate Summary
  • Amgen
  • Table 10-6: Amgen Corporate Summary
  • Anchiano Therapeutics
  • Table 10-7: Anchiano Therapeutics Corporate Summary
  • Apceth Biopharma GmbH & Co. KG
  • Table 10-8: Apceth Corporate Summary
  • Apollomics, Inc.
  • Table 10-9: Apollomics Corporate Summary
  • Aptevo Therapeutics
  • Table 10-10: Aptevo Corporate Summary
  • AstraZeneca PLC
  • Table 10-11: AstraZeneca Corporate Summary
  • Aurobindo Pharma Ltd.
  • Table 10-12: Aurobindo Corporate Summary
  • Bayer AG
  • Table 10-13: Bayer Corporate Summary
  • Bellicum Pharmaceuticals, Inc.
  • Table 10-14: Bellicum Pharmaceuticals Corporate Summary
  • Biocon Ltd
  • Table 10-15: Biocon Corporate Summary
  • BioInvent International AB
  • Table 10-16: BioInvent Corporate Summary
  • bluebird bio, Inc.
  • Table 10-17: bluebird bio Corporate Summary
  • Boehringer Ingelheim
  • Table 10-18: Boehringer Ingelheim Corporate Summary
  • Bristol-Myers Squibb Company
  • Table 10-19: Bristol-Myers Squibb Corporate Summary
  • Celgene Corporation
  • Table 10-20: Celgene Corporate Summary
  • Celldex Therapeutics
  • Table 10-21: Celldex Therapeutics Corporate Summary
  • Celltrion, Inc.
  • Table 10-22: Celltrion Corporate Summary
  • Celsion Corporation
  • Table 10-23: Celsion Corporate Summary
  • Clovis Oncology, Inc.
  • Table 10-24: Clovis Oncology Corporate Summary
  • Cold Genesys, Inc.
  • Table 10-25: Cold Genesys Corporate Summary
  • Dendreon Pharmaceuticals LLC
  • Table 10-26: Dendreon Corporate Summary
  • Eisai Co., Ltd.
  • Table 10-27: Eisai Corporate Summar
  • Eli Lilly & Company
  • Table 10-28: Eli Lilly Corporate Summary
  • EMD Serono, Inc. (Merck KgaA)
  • Table 10-29: EMD Serono Corporate Summary
  • Exelixis, Inc
  • Table 10-30: Exelixis Corporate Summar
  • Gamida Cell Ltd
  • Table 10-31: Gamida Cell Corporate Summar
  • Genprex, Inc
  • Table 10-32: Genprex Corporate Summar
  • Gilead Sciences, Inc.
  • Table 10-33: Gilead Sciences Corporate Summary
  • Immunomedics, Inc.
  • Table 10-34: Immunomedics Corporate Summary
  • Incyte Corporation
  • Table 10-35: Incyte Corporate Summary
  • Innate Pharma S.A.
  • Table 10-36: Innate Pharma Corporate Summary
  • Inovio Pharmaceuticals, Inc.
  • Table 10-37: Inovio Pharmaceuticals Corporate Summary
  • Johnson & Johnson
  • Table 10-38: Johnson & Johnson Corporate Summary
  • MacroGenics, Inc.
  • Table 10-39: MacroGenics Corporate Summary
  • Merck & Co., Inc.
  • Table 10-40: Merck & Co. Corporate Summary
  • Merrimack Pharmaceuticals, Inc.
  • Table 10-41: Merrimack Corporate Summary
  • Nascent Biotech
  • Table 10-42: Nascent Biotech Corporate Summary
  • Northwest Biotherapeutics, Inc.
  • Table 10-43: Northwest Biotherapeutics Corporate Summary
  • Novartis AG
  • Table 10-44: Novartis Corporate Summary
  • Oncolytics Biotech, Inc.
  • Table 10-45: Oncolytics Biotech Corporate Summary
  • OncoMed Pharmaceuticals, Inc.
  • Table 10-46: OncoMed Pharmaceuticals Corporate Summary
  • OncoSec Medical, Inc.
  • Table 10-47: OncoSec Medical Corporate Summary
  • Oncternal Therapeutics
  • Table 10-48: Oncternal Therapeutics Corporate Summary
  • Otsuka Holdings Co., Ltd.
  • Table 10-49: Otsuka Corporate Summary
  • Pfizer, Inc.
  • Table 10-50: Pfizer Corporate Summary
  • Puma Biotechnology, Inc.
  • Table 10-51: Puma Biotechnology Corporate Summary
  • Regeneron Pharmaceuticals
  • Table 10-52: Regeneron Corporate Summary
  • Roche (F. Hoffman-La Roche, Ltd.)
  • Table 10-53: Roche Corporate Summary
  • Sanofi
  • Table 10-54: Sanofi Corporate Summary
  • Seattle Genetics, Inc.
  • Table 10-55: Seattle Genetics Corporate Summary
  • Sesen Bio
  • Table 10-56: Sesen Bio Corporate Summary
  • Sorrento Therapeutics
  • Table 10-57: Sorrento Therapeutics Corporate Summary
  • Takeda Oncology - Millennium Pharmaceuticals
  • Table 10-58: Takeda Oncology Corporate Summary
  • TESARO, Inc.
  • Table 10-59: TESARO Corporate Summary
  • TG Therapeutics, Inc.
  • Table 10-60: TG Therapeutics Corporate Summary
  • Tocagen, Inc.
  • Table 10-61: Tocagen Corporate Summary
  • Vascular Biogenics Ltd.
  • Table 10-62: Vascular Biogenics Corporate Summary
  • ZIOPHARM Oncology, Inc.
  • Table 10-63: ZIOPHARM Oncology Corporate Summary
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
  • AbbVie, Inc.
  • Adaptimmune Therapeutics plc.
  • Advantagene, Inc.
  • Agenus, Inc.
  • Amgen
  • Anchiano Therapeutics
  • Apceth Biopharma GmbH & Co. KG
  • Apollomics, Inc.
  • Aptevo Therapeutics
  • AstraZeneca PLC
  • Aurobindo Pharma Ltd.
  • Bayer AG
  • Bellicum Pharmaceuticals, Inc.
  • Biocon Ltd
  • BioInvent International AB
  • bluebird bio, Inc.
  • Boehringer Ingelheim
  • Bristol-Myers Squibb Company
  • Celgene Corporation
  • Celldex Therapeutics
  • Celltrion, Inc.
  • Celsion Corporation
  • Clovis Oncology, Inc.
  • Cold Genesys, Inc.
  • Dendreon Pharmaceuticals LLC
  • Eisai Co., Ltd.
  • Eli Lilly & Company
  • EMD Serono, Inc. (Merck KgaA)
  • Exelixis, Inc.
  • Gamida Cell Ltd.
  • Genprex, Inc.
  • Gilead Sciences, Inc.
  • Immunomedics, Inc.
  • Incyte Corporation
  • Innate Pharma S.A.
  • Inovio Pharmaceuticals, Inc.
  • Johnson & Johnson
  • MacroGenics, Inc.
  • Merck & Co., Inc.
  • Merrimack Pharmaceuticals, Inc.
  • Nascent Biotech
  • Northwest Biotherapeutics, Inc.
  • Novartis AG
  • Oncolytics Biotech, Inc.
  • OncoMed Pharmaceuticals, Inc.
  • OncoSec Medical, Inc.
  • Oncternal Therapeutics
  • Otsuka Holdings Co., Ltd.
  • Pfizer, Inc.
  • Puma Biotechnology, Inc.
  • Regeneron Pharmaceuticals
  • Roche (F. Hoffman-La Roche, Ltd.)
  • Sanofi
  • Seattle Genetics, Inc.
  • Sesen Bio
  • Sorrento Therapeutics
  • Takeda Oncology – Millennium Pharmaceuticals
  • TESARO, Inc.
  • TG Therapeutics, Inc.
  • Tocagen, Inc.
  • Vascular Biogenics Ltd.
  • ZIOPHARM Oncology, Inc.
Note: Product cover images may vary from those shown
5 of 4
Note: Product cover images may vary from those shown
Order Online - visit: https://www.researchandmarkets.com/reports/4767214
Adroll
adroll